Powder: -20°C for 3 years | In solvent: -80°C for 1 year
(S,R,S)-AHPC-C6-PEG3-C4-Cl is a small molecule HaloPROTAC that incorporates the (S,R,S)-AHPC based VHL ligand and 3-unit PEG linker. (S,R,S)-AHPC-C6-PEG3-C4-Cl is capable of inducing the degradation of GFP-HaloTag7 in cell-based assays[1].
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
2 mg | ¥ 387 | 5日内发货 | ||
5 mg | ¥ 627 | 待询 |
产品描述 | (S,R,S)-AHPC-C6-PEG3-C4-Cl is a small molecule HaloPROTAC that incorporates the (S,R,S)-AHPC based VHL ligand and 3-unit PEG linker. (S,R,S)-AHPC-C6-PEG3-C4-Cl is capable of inducing the degradation of GFP-HaloTag7 in cell-based assays[1]. |
体外活性 | (S,R,S)-AHPC-C6-PEG3-C4-Cl uses the cereblon ligand[1]. The linker is 6-2-2-6. The linkers contain a mixture of hydrophobic and hydrophilic moieties to balance the hydrophobicity/hydrophilicity of the resulting hybrid compounds. PROTACs that induce the degradation of an oncogenic tyrosine kinase, BCR-ABL has been developed. (S,R,S)-AHPC-C6-PEG3-C4-Cl can be attached to potent TKIs (bosutinib and dasatinib) that mediate the degradation of c-ABL and BCR-ABL by hijacking either CRBN or VHL E3 ubiquitin ligase [2]. |
别名 | VH032-C6-PEG3-C4-Cl, VHL Ligand-Linker Conjugates 12, E3 ligase Ligand-Linker Conjugates 8 |
分子量 | 751.42 |
分子式 | C38H59ClN4O7S |
CAS No. | 1835705-55-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 100 mg/mL (133.08 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 1.3308 mL | 6.6541 mL | 13.3081 mL | 33.2703 mL |
5 mM | 0.2662 mL | 1.3308 mL | 2.6616 mL | 6.6541 mL | |
10 mM | 0.1331 mL | 0.6654 mL | 1.3308 mL | 3.327 mL | |
20 mM | 0.0665 mL | 0.3327 mL | 0.6654 mL | 1.6635 mL | |
50 mM | 0.0266 mL | 0.1331 mL | 0.2662 mL | 0.6654 mL | |
100 mM | 0.0133 mL | 0.0665 mL | 0.1331 mL | 0.3327 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
(S,R,S)-AHPC-C6-PEG3-C4-Cl 1835705-55-9 Others VH032-C6-PEG3-C4-Cl VHL Ligand-Linker Conjugates 12 AHPC-C6-PEG3-C4-Cl (S,R,S) AHPC C6 PEG3 C4 Cl E3 ligase Ligand-Linker Conjugates 8 (S,R,S)-AHPC-C-6-PEG3-C4-Cl (S,R,S)AHPCC6PEG3C4Cl Inhibitor inhibitor inhibit